Peoria, IL (July 27, 2019) – The Midwest Bioprocessing Center (MBC), a leading producer of unique carbohydrates for human health and nutrition, announced today that it has acquired the zuCarb™ Rare Sugars technology platform from zuChem Inc. Founded in 2003, zuChem’s long-term mission was to develop novel carbohydrate technology for a variety of food and pharmaceutical applications. This included the development of its zuCarb™ technology platform to produce rare sugars, activated sugars, and technology for glycodiversification of small molecules, proteins, and oligosaccharides. zuChem has now focused its commercial efforts and resources on the launch of its commercial xylitol program and transferred the zuCarb™ technology platform to the Midwest Bioprocessing Center.
Much of the technology was initially developed by Leila Aminova, Ph.D. and her colleagues who joined MBC from zuChem. “I am excited to be continuing the work we began at zuChem” said Dr. Aminova . “Access to this technology gives us dozens of products we can immediately start providing to pharmaceutical and academic researchers for drug discovery and glycobiology. It also allows us to carry out custom synthesis of sugars and glycoconjugates for a variety of applications”
For more information on zuCarb™ rare sugars please visit the Company’s website at www.mwbioprocessing.com.
About Midwest Bioprocessing Center, LLC.
The Midwest Bioprocessing Center is a start-up biotechnology company formed in 2019 to bring important new technologies to market for human health and nutrition. MBC’s proprietary technology includes the zuCarb™ Rare sugar platform which allows the production and modification of carbohydrates and glycochemicals that would otherwise be impractical or impossible to make. By expanding the number of sugar building blocks and components that are available to the marketplace—many of which are currently not available or prohibitively expensive—together with the synthetic tools to utilize these new sugars in human health and nutrition applications, the Midwest Bioprocessing Center enables both the discovery of breakthrough drugs as well as the cost-effective commercial production of many glycochemicals. The Midwest Bioprocessing Center is located in Peoria, IL and housed in the PeoriaNEXT Innovation Center. The Midwest Bioprocessing Center has facilities to carry out enzyme biocatalyisis, fermentation, chemical synthesis, and product purification; and can produce gram to kilogram scale quantities in-house. For more information please contact:
David Demirjian
801 W Main St
Peoria, IL 61606
